Evidence map›Paper›PMID 40106751›Full record

ArticlePloS one2025

Three hospitalized non-critical COVID-19 subphenotypes and change in intubation or death over time: A latent class analysis with external and longitudinal validation.

William S Stringer, Amy S Labar, Joshua D Geleris, Evan V Sholle, David A Berlin, Claire M McGroder, Matthew J Cummings, Max R O'Donnell, Haoyang Yi, Xuehan Yang and 3 more

Abstract readMulticenter Study
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

William S StringerDivision of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America.
Amy S LabarDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America.
Joshua D GelerisDivision of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America.
Evan V SholleDivision of Pulmonary and Critical Care Medicine, Weill Cornell University School of Medicine, New York, New York, United States of America.
David A BerlinDivision of Pulmonary and Critical Care Medicine, Weill Cornell University School of Medicine, New York, New York, United States of America.
Claire M McGroderDivision of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America.
Matthew J CummingsDivision of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America.
Max R O'DonnellDivision of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America.
Haoyang YiDepartment of Biostatistics, Columbia Mailman School of Public Health, New York, New York, United States of America.ORCID https://orcid.org/0009-0002-8847-8350
Xuehan YangDepartment of Biostatistics, Columbia Mailman School of Public Health, New York, New York, United States of America.
Ying WeiDepartment of Biostatistics, Columbia Mailman School of Public Health, New York, New York, United States of America.
Edward J SchenckDivision of Pulmonary and Critical Care Medicine, Weill Cornell University School of Medicine, New York, New York, United States of America.
Matthew R BaldwinDivision of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America.ORCID https://orcid.org/0000-0003-4670-3433

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Necroinflammatory Cell Death in SepsisK23HL151876 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHENCK, EDWARD JAMES · 2021 to 2025
$975k
Subtyping sepsis in Uganda using clinical, pathogen, and host response profilingK23AI163364 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CUMMINGS, MATTHEW JOHN · 2022 to 2025
$733k
Multimodal immune profiling to determine mechanisms of COVID-19 clinical trajectory in UgandaR21AI171249 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CUMMINGS, MATTHEW JOHN · 2022 to 2023
$445k
NCATS NIH HHS UL1 TR001873NHLBI NIH HHS K23 HL151876NIAID NIH HHS K23 AI163364NIAID NIH HHS R21 AI171249
6 · The paper itself

Abstract

backgroundThere are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown.

objectiveTo identify and validate non-critical COVID-19 subphenotypes at hospital admission that may elucidate pathobiology and facilitate heterogeneity-of-treatment effect analyses of clinical trials with non-critical COVID-19 patients.

methodsWe conducted a multi-center retrospective cohort study of adults hospitalized with COVID-19 who were not intubated or did not die within 24 hours of admission. We derived and externally and longitudinally validated subphenotypes during the wild-type and delta severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV2) waves via latent class analysis using clinical and laboratory data at hospital admission. We trained XGBoost machine learning models to predict subphenotype.

resultsWe analyzed data for 4,827 hospitalized non-critical COVID-19 patients: 2,077 wild-type wave Columbia University Medical Center (CUMC) and affiliate hospital derivation cohort patients; 1,214 wild-type wave Cornell Medical Center and affiliate hospital external validation cohort patients; and 1,536 delta wave CUMC and affiliate hospital longitudinal validation cohort patients. A three-class latent class model best fit each cohort identifying subphenotypes that were low-inflammatory, intermediate-inflammatory, and high-inflammatory with fibrinolysis, with increasing 90-day risk of intubation or death across subphenotypes in the wild-type wave. However, in the delta wave, the intermediate-inflammatory subphenotype had the lowest 90-day risk of intubation or death. XGBoost model area under the receiver-operating-curve was 0.96 in the testing dataset, and biomarkers of inflammation and cardiorenal dysfunction were the strongest predictors of subphenotype.

conclusionWe identified three hospitalized non-critical COVID-19 subphenotypes that persisted through the wild-type and delta SARS-CoV2 waves. The intermediate-inflammatory subphenotype had the greatest relative improvement in intubation and survival over time with the standardized use of corticosteroids and other interventions. Our machine learning model can facilitate heterogeneity-of-treatment effect analyses of clinical trials of adults hospitalized with non-critical COVID-19.

Indexed as

COVID-19AdultAgedFemaleHospitalizationHumansLatent Class AnalysisLongitudinal StudiesMachine LearningMaleMiddle AgedPhenotypeRetrospective StudiesSARS-CoV-2

Identifiers

PMID40106751
PMCPMC11922525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.